The International Agency for Research on Cancer and e-cigarette carcinogenicity: time for an evaluation

Braillon, Alain; Lang, Adam Edward

doi:10.1007/s10654-023-00993-7

Cited by 3 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies show a dose-dependent formation of DNA damage in oral cells from e-cigarette users who never smoked cigarettes. Those who used sweet, mint, menthol, and fruit-flavored e-liquids showed the highest level of DNA damage ( 4 ). Additional concerns include detrimental effects on the developing brain in young people who use e-cigarettes.…”

Section: Disproven Assumption Of 95% Risk Reduction In E-cigarettes C...mentioning

confidence: 99%

England Is Handing out E-Cigarettes: Is the “Swap to Stop” Tobacco Control Scheme Harm Reduction or Harm Production?

Lang,

Kathuria,

Braillon

et al. 2023

Am J Respir Crit Care Med

Self Cite

View full text Add to dashboard Cite

Section: Disproven Assumption Of 95% Risk Reduction In E-cigarettes C...mentioning

confidence: 99%

England Is Handing out E-Cigarettes: Is the “Swap to Stop” Tobacco Control Scheme Harm Reduction or Harm Production?

Lang,

Kathuria,

Braillon

et al. 2023

Am J Respir Crit Care Med

Self Cite

View full text Add to dashboard Cite

“…While normal cells follow a regulated process of growth, division, and cell death, cancer cells evade these controls . Cancer comes in diverse forms, and the most common types include lung, colorectal, stomach, liver, prostate, breast, cervical, and thyroid carcinoma. − Each type of cancer has its own set of characteristics regarding the affected organ or tissue, the behavior of cancer cells, and their tendency to metastasize (go beyond the initial or primary site of disease to invade adjacent parts of the body and organs). , Despite significant advances in cancer treatment, cancer remains the second leading cause of death worldwide, accounting for approximately 10 million deaths (or one in six deaths) each year according to the International Agency for Research on Cancer (IARC) . The induction of apoptosis or programmed cell death with anticancer drugs is one of the primary methods to kill cancerous cells .…”

Section: Introductionmentioning

confidence: 99%

“…11,12 Despite significant advances in cancer treatment, cancer remains the second leading cause of death worldwide, accounting for approximately 10 million deaths (or one in six deaths) each year according to the International Agency for Research on Cancer (IARC). 13 The induction of apoptosis or programmed cell death with anticancer drugs is one of the primary methods to kill cancerous cells. 14 However, the efficacy of apoptosis induction is compromised because malignant carcinoma may possess intrinsic resistance or acquired resistance to apoptosis.…”

Section: Introductionmentioning

confidence: 99%

Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer

Shi,

Chen,

2024

J. Med. Chem.

View full text Add to dashboard Cite

Ferroptosis is a type of iron-dependent programmed cell death characterized by the dysregulation of iron metabolism and the accumulation of lipid peroxides. This nonapoptotic mode of cell death is implicated in various physiological and pathological processes. Recent findings have underscored its potential as an innovative strategy for cancer treatment, particularly against recalcitrant malignancies that are resistant to conventional therapies. This article focuses on ferroptosis-based therapeutic strategies for precision cancer treatment, covering the molecular mechanisms of ferroptosis, four major types of ferroptosis inducers and their inhibitory effects on diverse carcinomas, the detection of ferroptosis by fluorescent probes, and their implementation in image-guided therapy. These state-of-the-art tactics have manifested enhanced selectivity and efficacy against malignant carcinomas. Given that the administration of ferroptosis in cancer therapy is still at a burgeoning stage, some major challenges and future perspectives are discussed for the clinical translation of ferroptosis into precision cancer treatment. ■ SIGNIFICANCE • The potential of ferroptosis as an innovative strategy for precision cancer therapy is highlighted. • Recent advances are discussed from three perspectives: molecular mechanism and regulation, anti-cancer ferroptosis inducers, and ferroptosis probes for image-guided therapy. • The strengths and weaknesses of ferroptosis modulators and probes are analyzed in terms of current progress and technical barriers. • Future perspectives are emphasized to advance ferroptosis-based therapies toward clinical use for cancer treatment.

show abstract

“…Similarly, e-cigarette use is a growing concern among patients with cancer; even more so, as there is accumulating evidence that e-cigarettes should be assessed by the International Agency for Research on Cancer (IARC) and classified as a group 2A agent (probably carcinogenic) or a group 2B agent (possibly carcinogenic) …”

mentioning

confidence: 99%

Substance Use Disorders Among Cancer Survivors

Braillon

2024

JAMA Oncol

Self Cite

View full text Add to dashboard Cite

To the Editor Jones and colleagues 1 should be commended for raising concerns about substance use disorders among adult cancer survivors. Indeed, this is a major comorbidity that impairs prognosis, and certainly there is room for improving its assessment and treatment: the PubMed search "substance use disorder and cancer" only retrieved 270 articles.However, it should not be forgotten that tobacco use is the most common substance use disorder in the US and globally. This oblivion is too frequent: only 75% of oncologists assess tobacco use at the intake visit, 60% advise patients to quit despite the fact that smoking seriously affects outcomes (eg, cancer treatment effectiveness, overall survival, risk of second primary malignant neoplasms, quality of life). 2 Furthermore, current tobacco use is associated with a range of other substance use and mental health problems; these relationships persist after accounting for a range of confounding variables. The presence of these other problems needs to be considered because they are likely to reduce the success of attempts to quit smoking. 3 Similarly, e-cigarette use is a growing concern among patients with cancer; 4 even more so, as there is accumulating evidence that e-cigarettes should be assessed by the International Agency for Research on Cancer (IARC) and classified as a group 2A agent (probably carcinogenic) or a group 2B agent (possibly carcinogenic). 5

show abstract

The International Agency for Research on Cancer and e-cigarette carcinogenicity: time for an evaluation

Abstract: Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Cited by 3 publications

References 5 publications

England Is Handing out E-Cigarettes: Is the “Swap to Stop” Tobacco Control Scheme Harm Reduction or Harm Production?

England Is Handing out E-Cigarettes: Is the “Swap to Stop” Tobacco Control Scheme Harm Reduction or Harm Production?

Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer

Substance Use Disorders Among Cancer Survivors

Contact Info

Product

Resources

About